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Ligand-induced monoubiquitination of  
BIK1 regulates plant immunity
Xiyu Ma1,2, Lucas A. N. Claus3,4, Michelle E. Leslie5,10,11, Kai Tao6,11, Zhiping Wu7,8,11, Jun Liu1,2,  
Xiao Yu2,9, Bo Li2,9, Jinggeng Zhou1,2, Daniel  V. Savatin3,4, Junmin Peng7,8, Brett M. Tyler6,  
Antje Heese5, Eugenia Russinova3,4, Ping He1,2 ✉ & Libo Shan2,9 ✉
Recognition of microbe-associated molecular patterns (MAMPs) by pattern 
recognition receptors (PRRs) triggers the first line of inducible defence against 
invading pathogens1–3. Receptor-like cytoplasmic kinases (RLCKs) are convergent 
regulators that associate with multiple PRRs in plants4. The mechanisms that underlie 
the activation of RLCKs are unclear. Here we show that when MAMPs are detected,  
the RLCK BOTRYTIS-INDUCED KINASE 1 (BIK1) is monoubiquitinated following 
phosphorylation, then released from the flagellin receptor FLAGELLIN SENSING 2 
(FLS2)–BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED KINASE 1 (BAK1) complex, 
and internalized dynamically into endocytic compartments. The Arabidopsis E3 
ubiquitin ligases RING-H2 FINGER A3A (RHA3A) and RHA3B mediate the 
monoubiquitination of BIK1, which is essential for the subsequent release of BIK1  
from the FLS2–BAK1 complex and activation of immune signalling. Ligand-induced 
monoubiquitination and endosomal puncta of BIK1 exhibit spatial and temporal 
dynamics that are distinct from those of the PRR FLS2. Our study reveals the 
intertwined regulation of PRR–RLCK complex activation by protein phosphorylation 
and ubiquitination, and shows that ligand-induced monoubiquitination contributes 
to the release of BIK1 family RLCKs from the PRR complex and activation of PRR 
signalling.
Prompt activation of PRRs upon microbial infection is essential for 
hosts to defend against pathogen attacks1–3. The Arabidopsis BIK1 fam-
ily of RLCKs are immune regulators associated with multiple PRRs, 
including the bacterial flagellin receptor FLS2 and the BAK1 and SERK 
family co-receptors5,6. Upon ligand perception, BIK1 is phosphoryl-
ated by BAK1 and subsequently dissociates from the FLS2–BAK1 
complex7. Downstream of the PRR complex, BIK1 phosphorylates 
plasma-membrane-resident NADPH oxidases to regulate the produc-
tion of reactive oxygen species (ROS)8,9, and phosphorylates the cyclic 
nucleotide-gated channels to trigger a rise in cytosolic calcium10. How-
ever, it remains unclear how the activation of BIK1 and its dynamic 
association with the PRR complex is regulated.
Ligand-induced increase in BIK1 puncta
BIK1–GFP localized both to the periphery of epidermal pavement cells 
and to intracellular puncta in Arabidopsis transgenic plants expressing 
functional 35S::BIK1-GFP analysed by spinning disc confocal micros-
copy (SDCM) (Fig. 1a, Extended Data Fig. 1a, b). BIK1–GFP colocalized 
with the FM4-64-stained plasma membrane (Fig. 1b), and frequently 
within endosomal compartments (Fig. 1b). Time-lapse SDCM showed 
that BIK1–GFP puncta were highly mobile, disappearing, appearing, 
and moving rapidly in and out of the plane of view (Extended Data 
Fig. 1c). The abundance of BIK1–GFP puncta increased over time 
(3–17 and 18–32 min) after treatment with the flagellin peptide flg22 
(Fig. 1c, Extended Data Fig. 1d–p). The timing of the ligand-induced 
increase in BIK1–GFP puncta differed from that of the increase in FLS2–
GFP puncta, which were significantly increased 35 min after flg22 treat-
ment11–13 (Fig. 1d). Ligand-induced endocytosis of FLS2 contributes 
to the degradation of the activated FLS2 receptor and attenuation 
of signalling11–14, whereas increased abundance of BIK1–GFP puncta 
precedes that of FLS2–GFP (Fig. 1c, d).
Ligand-induced BIK1 monoubiquitination
Ligand-induced FLS2 degradation is mediated by the U-box E3 ligases 
PUB12 and PUB13, which polyubiquitinate FLS215–17. We tested whether 
BIK1 is ubiquitinated upon treatment with flg22 using an in vivo ubiq-
uitination assay in Arabidopsis protoplasts that co-expressed FLAG 
epitope-tagged ubiquitin (FLAG–UBQ) and haemagglutinin (HA) 
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epitope-tagged BIK1 (Fig. 1e, Extended Data Fig. 2a). Treatment with 
flg22 induced ubiquitination of BIK1 (Fig. 1e), as ubiquitinated BIK1 
was detected by an anti-HA immunoblot upon immunoprecipitation 
with an anti-FLAG antibody. Flg22 also induced ubiquitination of BIK1 
in pBIK1::BIK1-HA transgenic plants (Extended Data Fig. 2b). The strong 
and discrete band of ubiquitinated BIK1 indicates monoubiquitina-
tion (Fig. 1e, Extended Data Fig. 2a, b), in contrast to the ladder-like 
smear of protein migration that indicates polyubiquitination of BAK1 
and FLS2 (Extended Data Fig. 2c, d). The apparent molecular mass of 
ubiquitinated BIK1 (about 52 kDa) is around 8 kDa larger than that of 
unmodified BIK1 (44 kDa), consistent with the attachment of a single 
ubiquitin to BIK1. Incubation with the catalytic domain of the mouse 
deubiquitinase USP2 (USP2-cc), but not its heat-inactivated form, 
reduced the molecular mass by about 8 kDa (Fig. 1e). We observed a 
similar pattern of ubiquitination of BIK1 when we used the UBQ(K0) 
variant, in which all seven lysine residues in UBQ were changed to 
arginine, thus preventing the formation of polyubiquitination chains 
(Extended Data Fig. 2e, f). Notably, flg22-induced ubiquitination of BIK1 
was blocked by treatment with the ubiquitination inhibitor PYR-41, 
but not by the proteasome inhibitor MG132, and was not observed in 
fls2 or bak1-4 mutants (Extended Data Fig. 2g–i). In addition to flg22, 
other MAMPs—including elf18, pep1, and chitin—also induced mon-
oubiquitination of BIK1 (Extended Data Fig. 2j), in line with the notion 
that BIK1 is a convergent component downstream of multiple PRRs4. 
Monoubiquitination of the BIK1 family RLCKs PBL1 and PBL10, but 
not of another RLCK, BSK1, was enhanced upon treatment with flg22 
(Extended Data Fig. 2k, l), suggesting that detection of MAMPs induces 
monoubiquitination of BIK1 family RLCKs.
Upon flg22 perception, BIK1 is phosphorylated5,6, as shown by an 
immunoblot mobility shift within 1 min with a plateau around 10 min 
(Fig. 1f). However, flg22-induced ubiquitination of BIK1 becomes appar-
ent only 10 min after treatment and reaches a plateau around 30 min 
(Fig. 1f), suggesting that flg22-induced ubiquitination of BIK1 may occur 
after its phosphorylation. BIK1 phosphorylation-deficient mutants, 
including a kinase-inactive mutant (BIK1(KM)) and two phospho-
rylation site mutants (BIK1(T237A) and BIK1(Y250A)) showed largely 
compromised flg22-induced ubiquitination (Fig. 1g). In addition, the 
kinase inhibitor K252a blocked flg22-induced ubiquitination of BIK1 
(Extended Data Fig. 3a). Plasma membrane localization is required for 
BIK1 ubiquitination, as BIK1(G2A), which bears a mutation of the myris-
toylation motif that is essential for plasma membrane localization, 
was not ubiquitinated upon flg22 treatment (Extended Data Fig. 3b, 
c). Together, these data suggest that flg22-induced phosphorylation 
of BIK1 is a prerequisite for its monoubiquitination at the plasma 
membrane.
BIK1 ubiquitination by RHA3A and RHA3B
There are 30 lysine residues in BIK1, each of which could potentially be 
ubiquitinated. We individually mutated 28 lysine residues to arginine 
(except for K105 and K106, which are located in the ATP-binding pocket 
and are required for kinase activity), and screened the mutants for 
flg22-induced ubiquitination. None of the individual K-to-R mutants 
blocked the ubiquitination of BIK1 without altering its kinase activity 
(Extended Data Fig. 3d). BIK1(K204R), in which flg22-induced BIK1 
monoubiquitination was compromised, also showed reduced phos-
phorylation in vivo and in vitro (Extended Data Fig. 3d, e). To identify 
BIK1-associated regulators, we carried out a yeast two-hybrid screen 
using BIK1(G2A) as bait, and identified RHA3A (AT2G17450), which 
encodes a functionally uncharacterized E3 ubiquitin ligase with a 
RING-H2 finger domain and an N-terminal transmembrane domain 
(Fig. 2a). We confirmed that BIK1 interacts with RHA3A using an in vitro 
pull-down assay (Fig. 2b), an in vivo co-immunoprecipitation (co-IP) 
assay in Arabidopsis protoplasts (Extended Data Fig. 4a), and co-IP in 
transgenic plants that expressed both BIK1 and RHA3A under their native 
promoters (Fig. 2c, Extended Data Fig. 4b). RHA3B (which is encoded 
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Fig. 1 | MAMP-induced BIK1 endocytosis and monoubiquitination.  
a, BIK1–GFP localizes to the cell periphery and intracellular puncta in 
maximum intensity projections of cotyledon epidermal cells (dashed box 
expanded in insert). Scale bar, 10 μm. b, BIK1–GFP colocalizes with FM4-64 in 
the plasma membrane (asterisk) and intracellular puncta (arrowheads).  
Scale bar, 5 μm. Pearson’s correlation coefficient for BIK1–GFP and FM4-64 
is 0.55 ± 0.14 (n = 35). c, d, BIK1 and FLS2 puncta increase after treatment with 
1 μM flg22. Mean ± s.e.m. overlaid on dot plots. n = 56, 48, 49, 47 images for 0, 
3–17, 18–32, 33–45 min of treatment, respectively, for BIK1–GFP (c) and n = 24, 
15, 21, 36, 34, 39, 39 images for 0, 5–15, 20–30, 35–45, 50–60, 65–75, 80–90 min 
of treatment, respectively, for FLS2–GFP (d). Scale bar, 5 μm (one-way analysis 
of variance (ANOVA)). e, Flg22 induces BIK1 monoubiquitination. Protoplasts 
from wild-type plants were transfected with plasmids expressing BIK1-HA  
and FLAG-UBQ, and were treated with 100 nM flg22 for 30 min. After 
immunoprecipitation (IP) with anti-FLAG agarose, ubiquitinated BIK1 was 
detected by immunoblot (IB) using anti-HA antibodies (lanes 1 and 2) or treated 
with GST–USP2-cc (lane 3). Heat-inactivated (HI) USP2-cc was used as a control 
(lane 4). Bottom panel shows BIK1–HA protein expression. Numbers on left 
show molecular mass (kDa). f, Time-course of flg22-induced BIK1 
phosphorylation and ubiquitination. Protoplasts expressing FLAG–UBQ and 
BIK1–HA were treated with 100 nM flg22 for the indicated times. BIK1 band 
intensities were quantified using Image Lab (Bio-Rad). Quantification of BIK1 
phosphorylation (under bottom panel) calculated as ratio of intensity of the 
upper band (pBIK1) to the sum intensities of shifted and non-shifted bands 
(pBIK1 + BIK1). Quantification of BIK1 ubiquitination (under top panel) 
calculated as relative intensity (fold change) of Ub–BIK1 bands (no treatment 
set to 1.0). g, BIK1 variants with impaired phosphorylation show compromised 
flg22-induced ubiquitination. All experiments were repeated at least three 
times with similar results.
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by AT4G35480) is the closest homologue of RHA3A, bearing 66% amino 
acid identity (Fig. 2a); RHA3B also co-immunoprecipitated with BIK1 
(Extended Data Fig. 4c). Flg22 treatment did not affect the interac-
tion between BIK1 and RHA3A or RHA3B (called RHA3A/B henceforth) 
(Extended Data Fig. 4a, c). Moreover, RHA3A/B co-immunoprecipitated 
with FLS2 (Extended Data Fig. 4d).
An in vitro ubiquitination assay showed that RHA3A had autoubiq-
uitination activity and monoubiquitinated itself (Extended Data 
Fig. 5a, b). Notably, glutathione-S-transferase (GST)–RHA3A, but not 
GST–RHA3A(I104A), in which a conserved isoleucine residue had been 
substituted, monoubiquitinated GST–BIK1–HA, as shown on immunob-
lots by an additional discrete band that migrated with an approximately 
8-kDa increase in molecular mass (Fig. 2d). The available rha3a and 
rha3b transfer DNA (T-DNA) insertion lines did not show a significant 
reduction in expression of the corresponding transcripts (Extended 
Data Fig. 5c). We therefore generated artificial microRNAs (amiRNAs) 
of RHA3A/B18. Co-expression of amiR-RHA3A and amiR-RHA3B, but not 
of amiR-RHA3A alone, suppressed flg22-induced monoubiquitina-
tion of BIK1 in protoplast transient assays (Extended Data Fig. 5d, e). 
Flg22-induced BIK1 monoubiquitination, but not phosphorylation, 
was also reduced in transgenic plants expressing amiR-RHA3A and 
amiR-RHA3B driven by the native promoters (Extended Data Fig. 5f, 
g). We also generated rha3a and rha3a/b mutants using the CRISPR–
Cas9 system (Extended Data Fig. 5h). Flg22-induced monoubiquitina-
tion of BIK1 was reduced in the rha3a/b mutant (Fig. 2e). These data 
indicate that RHA3A/B modulate flg22-induced monoubiquitination 
of BIK1.
Sites of RHA3A-mediated BIK1 ubiquitination
To identify sites of RHA3A-mediated BIK1 ubiquitination, we performed 
liquid chromatography-tandem mass spectrometry (LC–MS/MS) 
analysis of in vitro ubiquitinated BIK1. Among ten lysine residues iden-
tified (Fig. 3a, b,Extended Data Fig. 6a–i), K106 (which resides in the 
ATP-binding pocket) blocked BIK1 kinase activity when mutated7. Among 
the other nine lysine sites, all six lysines (K95, K170, K186, K286, K337, 
and K358) for which structural information is available19 are located 
on the surface of BIK1 (Fig. 3c). Furthermore, six ubiquitinated lysine 
residues were detected by LC–MS/MS of in vivo ubiquitinated BIK1–GFP 
upon treatment with flg22, and they all overlapped with those detected 
during in vitro RHA3A–BIK1 ubiquitination reactions (Extended Data 
Fig. 7a–h). Individual lysine mutations did not affect ubiquitination 
of BIK1 in vivo (Extended Data Fig. 3d), whereas combined mutations 
of the N-terminal five lysines (BIK1(N5KR)) or C-terminal four lysines 
(BIK1(C4KR)) partially compromised flg22-induced BIK1 ubiquitination. 
Mutation of all nine lysines in BIK1(9KR) largely blocked flg22-induced 
BIK1 monoubiquitination in vivo (Fig. 3d) and RHA3A-mediated in vitro 
ubiquitination (Fig. 3e). BIK1(9KR) showed similar activities to BIK1 
with regard to its in vitro kinase activity (Fig. 3f), flg22-induced BIK1 
phosphorylation, and association with RHA3A in protoplasts (Extended 
Data Fig. 8a, b). Furthermore, 35S::BIK19KR-HA/WT transgenic plants 
showed normal flg22-induced MAPK activation and ROS production 
(Extended Data Fig. 8c, d). Collectively, the data indicate that RHA3A 
monoubiquitinates BIK1 and that phosphorylation of BIK1 does not 
require monoubiquitination. Notably, BIK1 monoubiquitination may 
not be restricted to a single lysine, and multiple lysine residues could 
serve as monoubiquitin conjugation sites. Alternatively, monoubiqui-
tination might be the primary form of modification of BIK1, whereas 
polyubiquitinated BIK1 could be short-lived.
BIK1 monoubiquitination in immunity
BIK1(9KR), in which monoubiquitination but not phosphorylation 
of BIK1 is blocked, enabled us to examine the function of BIK1 mon-
oubiquitination without compromised kinase activity. We gener-
ated BIK19KR transgenic plants driven by the BIK1 native promoter in 
a bik1 background (pBIK1::BIK19KR-HA/bik1) (Extended Data Fig. 8e, 
f). Unlike pBIK1::BIK1-HA/bik1 transgenic plants, pBIK1::BIK19KR-HA/
bik1 transgenic plants exhibited a reduced flg22-triggered ROS burst 
similar to that of the bik1 mutant (Fig. 4a). Moreover, pBIK1::BIK19KR-HA/
bik1 transgenic plants were more susceptible to the bacterial path-
ogen Pseudomonas syringae pv. tomato (Pst) DC3000 hrcC− than 
were wild-type or pBIK1::BIK1-HA/bik1 transgenic plants (Fig. 4b). In 
addition, amiR-RHA3A/B transgenic plants exhibited compromised 
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and GST or GST–BAK1K (kinase domain) as the substrate. All experiments except 
MS analyses were repeated three times with similar results.
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Fig. 4 | RHA3A/B-mediated monoubiquitination of BIK1 contributes to its 
function in immunity and endocytosis. a, pBIK1::BIK19KR-HA/bik1 transgenic 
plants (lines 1 and 2) cannot complement bik1 for flg22-induced ROS 
production. One-way ANOVA; wild-type, BIK1/bik1: n = 53; bik1: n = 54; 
BIK1(9KR)/bik1: n = 55. In all panels, data are shown as mean ± s.e.m. overlaid on 
dot plot; lines beneath P values indicate relevant pairwise comparisons. b, The 
pBIK1::BIK19KR-HA/bik1 transgenic plants show increased bacterial growth of Pst 
DC3000 hrcC–. Plants were spray-inoculated and bacterial growth was measured 
at four days post-inoculation (dpi). One-way ANOVA, n = 6. CFU, colony-forming 
units. c, amiRNA-RHA3A/B plants show reduced flg22-induced ROS production. 
One-way ANOVA, n = 51. d, amiRNA-RHA3A/B plants show increased bacterial 
growth of Pst DC3000. Plants were hand-inoculated and bacterial growth was 
measured at 2 dpi. One-way ANOVA, n = 5. e, f, Flg22-induced endocytosis of 
BIK1, BIK1(9KR), and FLS2 in N. benthamiana leaf epidermal cells. e, BIK1–
TagRFP or BIK1(9KR)–TagRFP was co-expressed with FLS2–YFP followed by 
treatment with 100 μM flg22 and then imaged at the indicated time points by 
confocal microscopy. Scale bars, 20 μm. f, Quantification of BIK1–TagRFP 
(magenta) and FLS2–YFP (green) puncta. One-way ANOVA, additional images 
and n values shown in Extended Data Fig. 9c. g, BIK1(9KR) does not enable 
flg22-induced dissociation of BIK1 from FLS2. Top, co-IP was performed using 
protoplasts expressing FLS2–HA and BIK1–FLAG or BIK1(9KR)–FLAG, followed 
by treatment with 1 μM flg22 for 15 min. Bottom, the interaction of BIK1 with 
FLS2 was quantified as intensity from IP: anti-FLAG, IB: anti-HA divided by 
intensity from IP: anti-FLAG, IB: anti-FLAG. Mean ± s.e.m. fold change (BIK1 no 
treatment = 1.0; one-way ANOVA, n = 3). All experiments were repeated three 
times with similar results.
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flg22-triggered production of ROS and enhanced susceptibility to Pst 
DC3000 (Fig. 4c, d) and Pst DC3000 hrcC− and to the fungal pathogen 
Botrytis cinerea (Extended Data Fig. 8g, h). Similar results were obtained 
with the rha3a/b mutants (Extended Data Fig. 8i, j). Together, the data 
indicate that RHA3A/B-mediated monoubiquitination of BIK1 has a role 
in regulating ROS production and plant immunity.
BIK1 monoubiquitination in endocytosis
As detection of flg22 moderately increased BIK1–GFP endosomal 
puncta (Fig. 1c), we tested whether monoubiquitination of BIK1 is 
involved in flg22-triggered BIK1 endocytosis. Fewer FM4-64-labelled 
puncta were observed in plants expressing BIK1(9KR)–GFP than in 
those expressing BIK1–GFP after 10 or 15 min of treatment with flg22 
(Extended Data Fig. 9a, b). In addition, we compared the flg22-triggered 
endocytosis of BIK1–TagRFP and BIK1(9KR)–TagRFP when co-expressed 
with FLS2–YFP in Nicotiana benthamiana. As seen in transgenic plants 
(Fig. 1c, d), endosomal puncta of BIK1–TagRFP increased at 10–20 min, 
whereas FLS2–YFP puncta increased only after 60 min of flg22 treat-
ment (Fig. 4e, f, Extended Data Fig. 9c). A large portion (about 90%) of 
flg22-induced BIK1–TagRFP puncta did not colocalize with FLS2–YFP 
puncta (Extended Data Fig. 9d), suggesting that BIK1 and FLS2 are not 
likely to be internalized together. This is consistent with the differing 
ubiquitination characteristics of BIK1 and FLS2 (monoubiquitination 
versus polyubiquitination, 10 min versus 1 h). When compared to BIK1, 
BIK1(9KR)–TagRFP was more abundant in puncta before treatment, but 
the number of puncta did not increase after flg22 treatment (Fig. 4e, f, 
Extended Data Fig. 9c), indicating that internalization of BIK1(9KR)–
TagRFP does not respond to activation of PRRs. In addition, colocaliza-
tion of BIK1(9KR)–TagRFP with YFP-tagged ARA6 (a plant-specific Rab 
GTPase that resides on late endosomes20) was substantially reduced 
when compared to that of BIK1–TagRFP (Extended Data Fig. 9e, f). 
Notably, flg22-induced endocytosis of FLS2–YFP was absent in the 
presence of BIK1(9KR)–TagRFP (Fig. 4e, f). Together, our data sup-
port the conclusion that ligand-induced monoubiquitination of BIK1 
contributes to its internalization from the plasma membrane. Notably, 
whereas flg22 treatment induced phosphorylation-dependent dissocia-
tion of BIK1 from FLS25,6,21, this effect was largely absent in the case of 
BIK1(9KR) (Fig. 4g), consistent with the finding that BIK1(9KR) shows 
impaired FLS2 internalization (Fig. 4e, f). In addition, we observed 
an increase in the association between BIK1(9KR) and FLS2 without 
flg22 treatment (Fig. 4g). Treatment with the ubiquitination inhibitor 
PYR-41 also blocked flg22-induced dissociation of BIK1 from FLS2 and 
enhanced BIK1–FLS2 association (Extended Data Fig. 10a). Our data 
indicate that ligand-induced monoubiquitination of BIK1 has an impor-
tant role in dissociation of BIK1 from the plasma membrane-localized 
PRR complex, endocytosis of BIK1 and activation of immune signalling 
(Extended Data Fig. 10b).
Discussion
The BIK1 family RLCKs are central elements of plant PRR signalling, 
with many layers of regulation4,22. The stability of BIK1 is crucial for 
maintaining immune homeostasis. The plant U-box proteins PUB25 
and PUB26 polyubiquitinate BIK1 and regulate its stability in the steady 
state23. This module regulates the homeostasis of non-activated BIK1 
without affecting ligand-activated BIK123. We have identified a role of 
RHA3A/B in monoubiquitinating BIK1 and activating PRR signalling, 
which is distinct from that of PUB25 and PUB26. The levels of BIK1(9KR) 
proteins in transgenic plants and protoplasts are similar to those of 
wild-type BIK1 (Extended Data Fig. 10c, d), suggesting that monoubiq-
uitination of BIK1 may not regulate its stability. The nature of protein 
ubiquitination, including monoubiquitination and polyubiquitination, 
dictates the distinct fates of substrates, such as proteasome-mediated 
protein degradation, nonproteolytic functions of protein kinase activa-
tion, and membrane trafficking24. Ligand-induced polyubiquitination 
of FLS2 by PUB12 or PUB13 promotes degradation of FLS2, thereby 
attenuating immune signalling15,16, whereas ligand-induced monoubiq-
uitination of BIK1 triggers dissociation of BIK1 from PRR complexes and 
activates intracellular signalling. Thus, differential ubiquitination and 
endocytosis of distinct PRR–RLCK complex components are likely to 
serve as cues to fine-tune plant immune responses.
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Methods
No statistical methods were used to predetermine sample size. 
The experiments were not randomized and the investigators were 
not blinded to allocation during experiments and outcome assessment.
Plant materials and growth conditions
A. thaliana accession Col-0 (wild type, WT), mutants fls2, bak1-
4, bik1, transgenic pBIK1::BIK1-HA in the bik1 background, and 
pFLS2::FLS2-GFP in the Col-0 background have been described pre-
viously7,13. p35S::BIK-GFP and p35S::BIK19KR-GFP in the Col-0 back-
ground, pBIK1::BIK19KR-HA transgenic plants in the bik1 background, 
p35S::BIK1-HA, p35S::BIK19KR-HA transgenic plants in the Col-0 back-
ground, pBIK1::BIK1-HA in the Col-0 background, pBIK1::BIK1-HA/ 
pRHA3A::RHA3A-FLAG double transgenic plants in the Col-0 back-
ground and pRHA3A::amiR-RHA3A-pRHA3B::amiR-RHA3B transgenic 
plants in the Col-0 background were generated in this study (see below). 
All Arabidopsis plants were grown in soil (Metro Mix 366, Sunshine LP5 
or Sunshine LC1, Jolly Gardener C/20 or C/GP) in a growth chamber 
at 20–23 °C, 50% relative humidity and 75 μE m−2 s−1 light with a 12-h 
light/12-h dark photoperiod for four weeks before pathogen infection 
assay, protoplast isolation, and ROS assay. For confocal microscopy 
imaging, seeds were sterilized, maintained for 2 days at 4 °C in the 
dark, and germinated on vertical half-strength Murashige and Skoog 
(½MS) medium (1% (wt/vol) sucrose) agar plates, pH 5.8, at 22 °C in a 
16-h light/8-h dark cycle for 5 days with a light intensity of 75 μE m−2 s−1. 
For FM4-64 staining, whole seedlings were incubated for 15 min in 3 ml 
of ½MS liquid medium containing 2 μM FM4-64 and washed twice by 
dipping into deionized water before adding the elicitor (flg22, 100 nM). 
Wild-type tobacco (N. benthamiana) plants were grown under 14 h of 
light and 10 h of darkness at 25 °C.
Statistical analyses
Data for quantification analyses are presented as mean ± s.e.m. The 
statistical analyses were performed by Student’s t-test or one-way 
ANOVA test. The number of replicates is given in the figure legends.
Plasmid construction and generation of transgenic plants
FLS2, BAK1, BIK1, PBL1, PBL10 or BSK1 tagged with HA, FLAG or GFP in 
a plant gene expression vector pHBT used for protoplast assays, and 
FLS2CD, BAK1CD, BAK1K, PUB13, BIK1, or BIK1(KM) fused with GST or MBP 
used for Escherichia coli fusion protein isolation have been described 
previously5,7. BIK1 point mutations in a pHBT vector were generated 
by site-directed mutagenesis with primers listed in Supplementary 
Table 1 using the pHBT-BIK1-HA construct as the template. BIK1N5KR was 
constructed by sequentially mutating K41, K95, K170 and K186 into 
arginine on BIK1K31R. BIK1C4KR was constructed by sequentially mutat-
ing K337, K358 and K366 on BIK1K286R. pHBT-BIK1N5KR and pHBT-BIK1C4KR 
were then digested with XbaI and StuI and ligated together to gen-
erate pHBT-BIK19KR-HA. BIK19KR was sub-cloned into pHBT-FLAG or 
pHBT-GFP with BamHI and StuI digestion to generate pHBT-BIK19KR-FLAG 
or pHBT-BIK19KR-GFP. BIK19KR was sub-cloned into the binary vector 
pCB302-pBIK1::BIK1-HA or pCB302-35S::BIK1-HA with BamHI and 
StuI digestion to generate pCB302-pBIK1::BIK19KR-HA, or pCB302-
35S::BIK19KR-HA. BIK1-GFP or BIK19KR-GFP was sub-cloned into pCB302 
with BamHI and PstI digestion to generate pCB302-35S::BIK1-GFP and 
pCB302-35S::BIK19KR-GFP. BIK1K204R or BIK19KR was sub-cloned into a modi-
fied GST (pGEX4T-1, Pharmacia) vector with BamHI and StuI digestion 
to generate pGST-BIK1K204R or pGST-BIK19KR, respectively. BIK1-HA or 
BIK19KR-HA was further sub-cloned into the pGST vector as following: 
digestion with PstI, blunting end by T4 DNA polymerase, digestion 
with BamHI and ligation into a BamHI/StuI-digested pGST vector to 
generate pGST-BIK1-HA and pGST-BIK19KR-HA.
The RHA3A gene (AT2G17450) was cloned by PCR amplification from 
Col-0 complementary (c)DNAs with primers containing BamHI at the 
5′ end and StuI at the 3′ end, followed by BamHI and StuI digestion and 
ligation into the pHBT vector with an HA or FLAG tag at the C terminus. 
The RHA3B gene (AT4G35480) was cloned similarly to RHA3A using 
BamHI and SmaI-containing primers. pHBT-RHA3AI104A was generated 
by site-directed mutagenesis with primers listed in Supplementary 
Table 1. RHA3ACD (amino acids 50–186) and RHA3ACD/I104A were cloned 
by PCR amplification from RHA3A or RHA3AI104A, respectively, using 
BamHI- and StuI-containing primers. RHA3ACD and RHA3ACD/I104A were 
sub-cloned into pGST or a modified pMBP (pMAL-c2, NEB) vector with 
BamHI and StuI digestion for isolation of E. coli fusion proteins. The 
promoter of RHA3A or RHA3B was PCR-amplified from genomic DNAs 
of Col-0 with primers containing SacI and BamHI, and ligated into pHBT. 
The fragment of pRHA3A::RHA3A-FLAG was digested by SacI and EcoRI, 
and ligated into pCAMBIA2300.
AmiRNA constructs were generated as previously described18. In 
brief, amiRNA candidates were designed according to instructions 
at http://wmd3.weigelworld.org/cgi-bin/webapp.cgi. Three candi-
dates were chosen for each gene with RHA3A for amiRNA480: TTTTGT 
CAATACACTCCACGG; amiRNA211: TCAACGCAGATAAGAGCGCTA; 
amiRNA109: TCAAGTAATCTTGACGGTCGT, and RHA3B for amiRNA444: 
TTATGCATATTGCACACTCCG; amiRNA113: TAATCTAGAGGAGCGA 
GTCAG; amiRNA214: TCTACGCATACGAGAGCGCAT. Primers for clon-
ing amiRNAs were generated according to instructions at http://
wmd3.weigelworld.org/cgi-bin/webapp.cgi. The cognate fragments 
were cloned into the pHBT-amiRNA-ICE1 vector18. pCB302-pRHA3A:
:amiRNA-RHA3A-pRHA3B::amiRNA-RHA3B was constructed as follows: 
the RHA3A promoter was PCR amplified from pRHA3A::RHA3A-FLAG, 
digested with SacI and BamHI and ligated with pHBT-amiR-RHA3A 
to generate pHBT-pRHA3A::amiR-RHA3A. The pRHA3A::amiR-RHA3A 
fragment was further released by SacI and PstI digestion and ligated 
into pCB302 vector to generate pCB302-pRHA3A::amiRNA-RHA3A. 
pHBT-pRHA3B::amiR-RHA3B was constructed similarly followed 
by PCR amplification using a primer containing SacI sites at 
both the 5′ and 3′ends, subsequent digestion with SacI and liga-
tion into the pCB302-pRHA3A::amiRNA-RHA3A vector. Tandem 
pRHA3A/B-amiRNA-RHA3A/B in the same direction was confirmed by 
digestion and selected for further experiments.
The rha3a/b mutant was generated by the CRISPR–Cas9 system fol-
lowing the published protocol25. In brief, primers containing guide RNA 
(gRNA) sequences of RHA3A and RHA3B were used in PCR to insert both 
gRNA sequences into the pDT1T2 vector. The pDT1T2 vector containing 
both gRNAs was further PCR amplified, digested with BsaI and ligated 
into a binary vector pHEE401E. Agrobacterium-tumefaciens-mediated 
floral dip was used to transform the pHEE401E vector into Col-0 plants. 
Genomic DNAs from hygromycin (25 μg/ml)-positive plants were 
extracted, PCR amplified with gene-specific primers and sequenced 
by Sanger sequencing.
The monomer ubiquitin of Arabidopsis ubiquitin gene 10 
(UBQ10, At4g05320) carrying lysine-to-arginine mutations 
at all the seven lysine residues (UBQK0: 5′-ATGCAGATCTTTGT 
TAGGACTCTCACCGGAAGGACTATCACCCTCGAGGTGGAAAGCTCTGA 
CACCATCGACAACGTTAGGGCCAGGATCCAGGATAGGGAAGGTATTCC 
TCCGGATCAGCAGAGGCTTATCTTCGCCGGAAGGCAGTTGG AGGATGG 
CCGCACGTTGGCGGATTACAATATCCAGAGGGAATCCA CCCTCCACTT 
GGTCCTCAGGCTCCGTGGTGGTTAA-3′) was synthesized and cloned 
into a pUC57 vector by GenScript USA Incorporation. UBQK0 was then 
amplified by PCR with primers listed in the Supplementary Table 1 and 
further sub-cloned into a modified pHBT vector with BamHI and PstI 
digestion to generate pHBT-FLAG-UBQK0.
Plasmids used for transient expression in N. benthamiana were 
constructed as reported previously26. In brief, FLS2, BIK1, and 
BIK19KR were PCR amplified and recombined into pDONR207-YFP, 
pDONR207-TagRFP, and pDONR207-GFP vectors by In-Fusion HD Clon-
ing (TaKaRa Bio). The pDONR207 vectors were subsequently transferred 
to a destination vector pmAEV (derived from binary vector pCAMBIA  
with a 35S promoter) using the Gateway LR reaction (Thermo Fisher 
scientific).
DNA fragments cloned into the final constructs were confirmed 
via Sanger sequencing. A.-tumefaciens-mediated floral dip was used 
to transform the above binary vectors into bik1 or Col-0 plants. 
The transgenic plants were selected using glufosinate-ammonium 
(Basta, 50 μg/ml) for the pCB302 vector or kanamycin (50 μg/ml) for 
the pCAMBIA2300 vector. Multiple transgenic lines were analysed by 
immunoblotting for protein expression. Two lines with 3:1 segregation 
ratios for antibiotic resistance in the T3 generation were selected to 
obtain homozygous seeds for further studies. amiR-RHA3A/B trans-
genic plants that were resistant to Basta in the T2 generation were used 
for assays.
Yeast two-hybrid screen
The cDNA library constructed in a modified pGADT7 vector (Clontech) 
has been previously described15. BIK1(G2A) from pHBT-BIK1G2A-HA was 
sub-cloned into a modified pGBKT7 vector with BamHI and StuI diges-
tion. pGBK-BIK1G2A was transformed into the yeast AH109 strain. The 
resulting yeast transformants were then transformed with the cDNA 
library and screened in synthetic defined (SD) medium without Trp, 
Leu, His, Ade (SD-T-L-H-A) and SD-T-L-H containing 1 mM 3-amino-1, 
2, 4-triazole (3-AT). The confirmed yeast colonies were subjected to 
plasmid isolation and sequencing.
Pathogen infection assays
Pst DC3000 was cultured overnight at 28 °C in King’s B medium sup-
plemented with rifamycin (50 μg/ml). Bacteria were collected by 
centrifugation at 3,000g, washed and re-suspended to a density of 
106 colony-forming units (cfu)/ml with 10 mM MgCl2. Leaves from 
four-week-old plants were hand-inoculated with bacterial suspen-
sion using a needleless syringe. To measure in planta bacterial growth, 
five to six sets of two leaf discs, 6 mm in diameter, were punched and 
ground in 100 μl ddH2O. Serial dilutions were plated on TSA plates 
(1% tryptone, 1% sucrose, 0.1% glutamatic acid and 1.8% agar) con-
taining 25 μg/ml rifamycin. Plates were incubated at 28 °C and bacte-
rial cfu were counted 2 days after incubation. For spray inoculation, 
Pst DC3000 or Pst DC3000 hrcC− bacteria were collected and 
re-suspended to 5 × 108 cfu/ml with 10 mM MgCl2, silwet L-77 (0.02%) 
and sprayed onto the leaf surface. Plants were covered with a transpar-
ent plastic dome to maintain humidity after spraying. After incubation, 
the third pair of true leaves was detached, soaked in 70% ethanol for 
30 s and rinsed in water, and bacterial growth was measured as 
described above.
Protoplast transient expression and co-IP assays
Protoplast isolation and the transient expression assay have been 
described previously27. For protoplast-based co-IP assays, protoplasts 
were transfected with a pair of constructs (the empty vectors as con-
trols, 100 μg DNA for 500 μl protoplasts at a density of 2 × 105/ml for 
each sample) and incubated at room temperature for 6–10 h. After 
treatment with flg22 at the indicated concentrations and time points, 
protoplasts were collected by centrifugation and lysed in 300 μl co-IP 
buffer (150 mM NaCl, 50 mM Tris-HCl, pH7.5, 5 mM EDTA, 0.5% Triton, 
1 × protease inhibitor cocktail, before use, adding 2.5 μl 0.4 M DTT, 
2 μl 1 M NaF and 2 μl 1 M Na3VO3 for 1 ml IP buffer) by vortexing. 
After centrifugation at 10,000g for 10 min at 4 °C, 30 μl superna-
tant was collected for input controls and 7 μl anti-FLAG–agarose 
beads were added to the remaining supernatant and incubated at 
4 °C for 1.5 h. Beads were collected and washed three times with 
washing buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 
0.5% Triton) and once with 50 mM Tris-HCl, pH 7.5. Immunoprecipi-
tates were analysed by immunoblotting with the indicated antibod-
ies. The amiRNA candidate screens were performed as previously 
described18.
In vivo ubiquitination assay
FLAG-tagged UBQ (FLAG–UBQ) or a vector control (40 μg DNA) was 
co-transfected with the target gene with an HA tag (40 μg DNA) into 400 μl 
protoplasts at a density of 2 × 105/ml for each sample, and protoplasts 
were incubated at room temperature for 6–10 h. After treatment with 
100 nM flg22 at the indicated time points, protoplasts were collected for 
co-IP assay in co-IP buffer containing 1% Triton X-100. PYR-41 (Sigma, cat 
# N2915) was added at the indicated concentrations and time points 
(see Figure legends).
Recombinant protein isolation and in vitro kinase assays
Fusion proteins were produced from E. coli BL21 at 16 °C using LB 
medium with 0.25 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). 
GST fusion proteins were purified with Pierce glutathione agarose 
(Thermo Scientific), and MBP fusion proteins were purified using amyl-
ose resin (New England Biolabs) according to the standard protocol 
from companies. The in vitro kinase assays were performed with 0.5 μg 
kinase proteins and 5 μg substrate proteins in 30 μl kinase reaction 
buffer (10 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 2.5 mM EDTA, 50 mM NaCl, 
0.5 mM DTT, 50 μM ATP and 1 μCi [γ -32P] ATP). After gentle shaking at 
room temperature for 2 h, samples were denatured with 4 × SDS load-
ing buffer and separated by 10% SDS–PAGE gel. Phosphorylation was 
analysed by autoradiography.
In vitro ubiquitination assay
Ubiquitination assays were performed as previously described with 
modifications28. Reactions containing 1 μg substrate, 1 μg HIS6–E1 
(AtUBA1), 1 μg HIS6–E2 (AtUBC8), 1 μg GST–E3, 1 μg ubiquitin (Boston 
Biochem, cat # U-100AT-05M) in the ubiquitination reaction buffer 
(20 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 0.5 mM DTT, 2 mM ATP) were 
incubated at 30 °C for 3 h. The ubiquitinated proteins were detected 
by immunoblotting with indicated antibodies. The rabbit monoclo-
nal anti-RHA3A antibody was generated according to the company’s 
standard protocol against the peptide: AGGDSPSPNKGLKKC 
(GenScript).
In vitro deubiquitination assay
Mouse USP2-cc was cloned by PCR amplification from mouse cDNAs 
with primers containing BamHI at the 5′ end and SmaI at the 3′ end, fol-
lowed by BamHI and SmaI digestion and ligation into the pGST vector to 
construct pGST-Usp2-cc. GST–USP2-cc fusion proteins were produced 
in E. coli BL21 and purified with Pierce glutathione agarose (Thermo 
Scientific) according to the manufacturer’s standard protocol. Deubiq-
uitination (DUB) assays were performed as previously described with 
modifications29. In brief, an in vitro ubiquitination assay was performed 
overnight at 28 °C as described above. The reaction was aliquoted into 
individual tubes containing USP2-cc or heat-inactivated (HI) (95 °C for 
5 min) USP2-cc as a control in the DUB reaction buffer (50 mM Tris-HCl, 
pH 7.5, 50 mM NaCl and 5 mM DTT) and incubated at 28 °C for 5 h. Sam-
ples were then denatured and analysed by immunoblotting.
For in vitro DUB assay with flg22-induced ubiquitinated BIK1, BIK1–
HA and FLAG–UBQ were expressed in Arabidopsis protoplasts treated 
with 100 nM flg22 for 30 min. The ubiquitinated BIK1–HA proteins were 
immunoprecipitated as described above. After washing with 50 mM 
Tris-HCl, agarose beads were washed once with DUB dilution buffer 
(25 mM Tris-HCl, pH 7.5, 150 mM NaCl and 10 mM DTT) and mixed with 
GST–USP2-cc in DUB reaction buffer. After overnight incubation, beads 
were denatured in SDS buffer and analysed by immunoblotting.
MAPK assay
Five 11-day-old Arabidopsis seedlings per treatment, grown on vertical 
plates with ½MS medium, were transferred into water overnight before 
flg22 treatment. Seedlings were collected, drilled and lysed in 100 μl 
co-IP buffer. Protein samples with 1 × SDS buffer were separated in 10% 
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SDS–PAGE gel to detect pMPK3, pMPK6 and pMPK4 by immunoblotting 
with anti-pERK1/2 antibody (Cell Signaling, cat # 9101).
Detection of ROS production
The third or fourth pair of true leaves from 4- to 5-week-old soil-grown 
Arabidopsis plants were punched into leaf discs (diameter 5 mm). Leaf 
discs were incubated in 100 μl ddH2O with gentle shaking overnight. 
Water was replaced with 100 μl reaction solution containing 50 μM 
luminol, 10 μg/ml horseradish peroxidase (Sigma-Aldrich) supple-
mented with or without 100 nM flg22. Luminescence was measured 
with a luminometer (GloMax-Multi Detection System, Promega) with 
a setting of 1 min as the interval for 40–60 min. Detected values of 
ROS production were indicated as means of relative light units (RLU).
In vitro GST pull-down assay
GST or GST–BIK1 agarose beads were obtained after elution and washed 
with 1 × PBS (137 mM NaCl, 2.7 mM KCl, 15 mM Na2HPO4, 4.4 mM KH2PO4) 
three times. HA-tagged MBP-RHA3ACD or MBP proteins (2 μg) were 
pre-incubated with 10 μl prewashed glutathione agarose beads in 300 μl 
pull-down incubation buffer (20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 0.1 
mM EDTA, and 0.2% Triton X-100) for 30 min at 4 °C. Five microlitres of 
GST or GST–BIK1 agarose beads were pre-incubated with 20 μg bovin 
serum albumin (BSA, Sigma, cat # A7906) in 300 μl incubation buffer 
for 30 min at 4 °C with gentle shaking. The supernatant containing 
MBP-RHA3ACD or MBP was incubated with pre-incubated GST or GST–
BIK1 agarose beads for 1 h at 4 °C with gentle shaking. The agarose beads 
were precipitated and washed three times in pull-down wash buffer 
(20 mM Tris-HCl, pH 7.5, 300 mM NaCl, 0.1 mM EDTA, and 0.5% Triton 
X-100). The pulled-down proteins were analysed by immunoblotting 
with an anti-MBP antibody (Biolegend, cat # 906901).
Mass spectrometry analysis of ubiquitination sites
In vitro ubiquitination reactions with GST–RHA3ACD and GST–BIK1 
or GST–BIK1(K204R) were performed as mentioned above with over-
night incubation. Reactions were loaded on an SDS–PAGE gel (7.5%) 
and ran for a relatively short time until the ubiquitinated bands could 
be separated from the original GST–BIK1 (GST–BIK1 band ran less than 
0.5 cm from the separating gel). Ubiquitinated bands were sliced and 
trypsin-digested before LC–MS/MS analysis on an LTQ-Orbitrap hybrid 
mass spectrometer (Thermo Fisher) as previously described30. The MS/
MS spectra were analysed with SEQUEST software, and images were 
exported from SEQUEST.
In vivo BIK1 ubiquitination sites were identified as follows: 20 ml of 
wild-type Arabidopsis protoplasts at a concentration of 2 × 105 per ml 
were transfected with BIK1–GFP and FLAG–UBQ and the protoplasts 
were treated with 200 nM flg22 for 30 min after 7 h of incubation. 
GFP-trap-Agarose beads (Chromotek, cat # gta-20) were incubated 
with cell lysates at a ratio of 10 μl beads to 4 × 105 cells for 1 h at 4 °C 
and beads were pooled from 10 tubes, washed using IP buffer three 
times, and denatured in SDS buffer. Samples were separated by 10% 
SDS–PAGE and stained with GelCode Blue Stain Reagent (Thermo 
Fisher cat # 24590). Ubiquitinated bands were sliced and analysed as 
described above.
Confocal microscopy and image analysis
For laser scanning confocal microscopy, images were taken using a 
Leica SP8X inverted confocal microscope equipped with a HC PL APO 
CS2 40×/1.10 and 63×/1.20 water-corrected objective. The excitation 
wavelength was 488 nm for both GFP and FM4-64 (Thermo Fisher 
T13320), 514 nm for YFP and 555 nm for TagRFP using the white light 
laser. Emission was detected at 500–530 nm for GFP, 570–670 nm for 
FM4-64, 519–549 nm for YFP, and 569–635 nm for TagRFP by using 
Leica hybrid detectors. Autofluorescence was removed by adjusting the 
time gate window between 0.8 and 6 ns. Intensities were manipulated 
using ImageJ software.
For SDCM, image series were captured using a custom Olympus IX-71 
inverted microscope equipped with a Yokogawa CSU-X1 5,000 rpm 
spinning disc unit and 60× silicon oil objective (Olympus UPlanSApo 
60×/1.30 Sil) as previously described11. For the custom SDCM system, 
GFP and FM4-64 were excited with a 488-nm diode laser and fluores-
cence was collected through a series of Semrock Brightline 488-nm 
single-edge dichroic beamsplitter and bandpass filters: 500–550 nm 
for GFP and 590–625 nm for FM4-64. Camera exposure time was set to 
150 ms. For each image series, 67 consecutive images at a z-step interval 
of 0.3 μm (20 μm total depth) were captured using Andor iQ2 software 
(Belfast, UK). Images captured by custom SDCM were processed with 
the Fiji distribution of ImageJ 1.51 (https://fiji.sc/) software, and BIK1–
GFP and FLS2–GFP endosomal puncta were quantified as the number 
of puncta per 1,000 μm2 as previously described11,31, with the exception 
that puncta were detected within a size distribution of 0.1–2.5 μm2. For 
colocalization of BIK1–GFP with FM4-64 by custom SDCM, cotyledons 
were stained with 2.5 μM FM4-64 for 10 min, washed twice, and imaged 
after a 5-min chase.
For quantification of flg22-induced puncta containing BIK1–
GFP or BIK1(9KR)-GFP over time, the maximum number of FM4-64 
labelled spots per image area was set to 100%, and the percentage of 
GFP-colocalizing spots per time interval relative to the maximum was 
calculated; 20–25 images per time interval, captured from 5 individual 
plants per genotype were used for quantification.
For transient expression in N. benthamiana, Agrobacterium strain C58 
carrying the constructs of interest was co-infiltrated in the abaxial side 
of tobacco leaves as described previously32. Between 48 and 72 h after 
infiltration, multiple infiltrated leaves were treated with 100 μM flg22 
and imaged at the indicated time points. The number of puncta per 
1,000 μm2 was quantified as previously described11,31. The percentage 
colocalization of BIK1 and FLS2 was calculated by dividing the number 
of BIK1–FLS2 colocalizing puncta by the total number of BIK1 puncta. 
The percentage colocalization of BIK1 and ARA6 was calculated by 
dividing the number of BIK1–ARA6 or BIK1(9KR)–ARA6 colocalizing 
puncta by the total number of ARA6 puncta.
qRT–PCR analysis
Total RNA was isolated from the leaves of four-week-old plants with 
TRIzol reagent (Invitrogen). One microgram of total RNA was treated 
with RNase-free DNase I (New England Biolabs) followed by cDNA syn-
thesis with M-MuLV reverse transcriptase (New England Biolabs) and 
oligo(dT) primer. qRT–PCR analysis was performed using iTaq SYBR 
green Supermix (Bio-Rad) with primers listed in Supplementary Table 1 
in a Bio-Rad CFX384 Real-Time PCR System. The expression of RHA3A 
and RHA3B was normalized to the expression of ACTIN2.
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
Data availability
The data supporting the findings of this study are available within the 
paper and its Supplementary Information files. Source Data (gels and 
graphs) for Figs. 1–4 and Extended Data Figs. 1–10 are provided with 
the paper.
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Extended Data Fig. 1 | BIK1–GFP is functional in plants and undergoes 
endocytosis. a, BIK1–GFP is functional, as confirmed by BIK1 phosphorylation 
in 35S::BIK1-GFP-expressing Col-0 cotyledons after treatment with 1 μM flg22. 
MPK6 is a loading control and the black stippled line indicates discontinuous 
segments from the same gel. b, BIK1–GFP restored ROS production in bik1 
leaves upon flg22 treatment. Leaf discs from wild-type, bik1 and BIK1–GFP 
complementation plants (lines 1 and 2) were treated with 100 nM flg22 for ROS 
measurement using a luminometer over 50 min. Data are shown as 
mean ± s.e.m. (wild-type, bik1: n = 42; BIK1–GFP/bik1: n = 45). c, Time-lapse 
SDCM shows that BIK1–GFP endosomal puncta are highly mobile with puncta 
that disappear (red circle), appear (yellow circle), and rapidly move in and out of 
the plane of view (white circle). Scale bar, 5 μm. d–k, BIK1–GFP localizes to 
endosomal puncta and plasma membrane in cross-sectional images of 
epidermal cells. The abaxial epidermal cells of cotyledons expressing  
BIK1–GFP were imaged with SDCM with a Z-step of 0.3 μm. A subset of the 
cross-sectional images is shown at the indicated depths (3, 6, 9, 12, 15, 18 and 21 
μm) along with the maximum-intensity projection (MIP) of all 67 images 
through the epidermis. BIK1–GFP localizes to both plasma membrane and 
endosomal puncta (white arrows) within all sections. k–p, Method for 
quantification of BIK1–GFP puncta within MIPs of SDCM images. k, MIPs were 
generated using Fiji distribution of ImageJ 1.51 (https://fiji.sc/) for each Z-series 
captured by SDCM imaging of BIK1–GFP cotyledons. l, Regions of MIP with 
non-pavement cells (for example, stomata) were removed from the image using 
the line draw and crop functions. The total surface area (μm2) of the image was 
measured using the analyze measure function. m, Puncta within the cropped 
MIP were recognized using a customized model generated and applied with the 
Trainable Weka Segmentation plug-in for Fiji. The same model was applied to 
all images to generate binary images showing the physical locations of all  
BIK1–GFP puncta (black). n–o, Puncta within the size range 0.1–2.5 μm2 were 
highlighted in green (n) and counted (o) using the analyze particles function in 
Fiji. BIK1–GFP endocytosis was quantified as the number of puncta per 1,000 μm2. 
p, An overlay of the BIK1–GFP puncta (yellow highlight) over the cropped MIP 
confirmed correct identification of puncta. The experiments in a–c were 
repeated three times with similar results.
Extended Data Fig. 2 | MAMP-triggered monoubiquitination of BIK1-family 
RLCK proteins. a, Flg22 induces monoubiquitination of BIK1. Protoplasts 
from wild-type plants were transfected with BIK1–HA and FLAG–UBQ or a 
vector (Ctrl), and then treated with 100 nM flg22 for 30 min. After 
immunoprecipitation with anti-FLAG agarose, ubiquitinated BIK1 was detected 
by immunoblotting using anti-HA antibody (top). Middle, BIK1–HA proteins; 
bottom, CBB staining for RuBisCO (RBC). b, Flg22 induces BIK1 
monoubiquitination in pBIK1::BIK1-HA transgenic plants. Protoplasts from 
pBIK1::BIK1-HA/bik1 transgenic plants were transfected with FLAG–UBQ and 
then treated with 100 nM flg22 for 30 min. After immunoprecipitation with 
anti-FLAG agarose, ubiquitinated BIK1 was detected by immunoblotting with 
anti-HA antibody (top). Bottom, BIK1–HA proteins. c, BAK1 is constitutively 
polyubiquitinated in vivo. Protoplasts from wild-type plants were transfected 
with BAK1–HA and FLAG–UBQ or control, and then treated with 100 nM flg22 
for 30 min. Immunoprecipitation was carried out with anti-FLAG agarose. 
Ubn-BAK1 proteins were detected as a smear with anti-HA immunoblotting 
(top). Middle, BAK1–HA proteins; bottom, CBB staining for RBC. d, Flg22 
induces FLS2 polyubiquitination. Protoplasts from wild-type plants were 
transfected with FLS2–HA and FLAG–UBQ and then treated with 100 nM flg22 
for 30 min. e, f, Monoubiquitination of BIK1 with UBQ(K0). Protoplasts from 
pBIK1::BIK1-HA (e) or 35S::BIK1-HA (f) transgenic plants were transfected with 
FLAG–UBQ(K0) (all lysine residues mutated to arginine) and then treated with 
100 nM flg22 for 30 min. The mutations of lysine to arginine in UBQ(K0) are 
shown at the top of e with amino-acid positions labelled. g, PYR-41 blocks 
flg22-induced BIK1 monoubiquitination. PYR-41 (50 μM) was added 30 min 
before flg22 treatment. h, Flg22 induces BIK1 monoubiquitination in the 
presence of MG132. MG132 (2 μM) was added 1 h or 2.5 h before treatment with 
flg22. i, Flg22-induced BIK1 monoubiquitination depends on FLS2 and BAK1. 
Protoplasts isolated from wild-type, fls2 or bak1-4 plants were transfected with 
BIK1–HA and FLAG–UBQ and then treated with 100 nM flg22 for 30 min. j, elf18, 
pep1 and chitin induce BIK1 monoubiquitination. 1 μM elf18, 200 nM pep1 or 
100 μg/ml chitin was added to protoplasts for 30 min. k, The BIK1 homologue 
PBL1 is monoubiquitinated upon treatment with flg22. PBL1–HA and FLAG–
UBQ were expressed in protoplasts. l, Flg22 induces monoubiquitination  
of the BIK1-family RLCK PBL10 but not of BSK1. HA-tagged PBL10 or BSK1 was 
expressed with FLAG–UBQ in wild-type protoplasts. Experiments were 
repeated at least three times with similar results.
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Extended Data Fig. 3 | Plasma membrane localization and phosphorylation 
are required for BIK1 ubiquitination. a, The kinase inhibitor K252a blocks 
flg22-induced ubiquitination of BIK1. Protoplasts transfected with FLAG–UBQ 
and BIK1–HA were treated with 1 μM K252a for 30 min and then with 100 nM 
flg22. b, BIK1(G2A) no longer localizes to the plasma membrane. BIK1–YFP or 
BIK1(G2A)–YFP was expressed in N. benthamiana for imaging analysis.  
c, BIK1(G2A) show compromised flg22-induced monoubiquitination. BIK1–HA 
or BIK1(G2A)–HA was co-expressed with FLAG–UBQ in protoplasts. d, Single 
K-to-R mutations of BIK1 fail to block flg22-induced ubiquitination without 
altering kinase activity. HA-tagged wild-type or mutant BIK1 was co-expressed 
with FLAG–UBQ in protoplasts. e, BIK1(K204R) exhibits reduced 
autophosphorylation and phosphorylation of BAK1. An in vitro kinase assay 
was performed using GST–BIK1 or GST–BIK1(K204R) as a kinase and GST or 
GST–BAK1K (BAK1 kinase domain without detectable autophosphorylation 
activity) as a substrate with [γ-32P] ATP. Top, proteins were separated with SDS–
PAGE and analysed by autoradiography (Autorad.); bottom, protein loading 
shown CBB staining. Experiments were repeated at least twice with similar 
results.
Extended Data Fig. 4 | RHA3A/B interacts with BIK1 in vivo. a, BIK1 interacts 
with RHA3A in a co-IP assay. RHA3A–HA was co-expressed with BIK1–FLAG or 
control in protoplasts and then treated with 100 nM flg22 for 15 min. Left, the 
co-IP assay was carried out with anti-FLAG agarose and immunoprecipitated 
proteins were immunoblotted with anti-HA or anti-FLAG antibody. Right,  
BIK1–FLAG and RHA3A–HA proteins. b, RHA3A expression (mean ± s.e.m.) in 
pRHA3A::RHA3A-FLAG/pBIK1::BIK1-HA transgenic plants. qRT–PCR was carried 
out to detect RHA3A transcripts using ACTIN2 as a control. Relative gene 
expression in wild-type (set as 1), pBIK1::BIK1-HA (Ctrl) and two independent 
transgenic lines (lines 7 and 10) is shown. One-way ANOVA, n = 3. c, BIK1 
associates with RHA3B independent of flg22 treatment. RHA3B–HA was 
co-expressed with BIK1–FLAG or control in protoplasts and then treated with 
100 nM flg22 for 15 min. Left, co-IP assay was carried out with anti-FLAG 
agarose and immunoprecipitated proteins were immunoblotted with anti-HA 
or anti-FLAG antibody. Right, BIK1–FLAG and RHA3B–HA proteins before 
immunoprecipitation. d, FLS2 interacts with RHA3A and RHA3B in a co-IP 
assay. Experiments were repeated three times with similar results.
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Extended Data Fig. 5 | RHA3A/B ubiquitinate BIK1 in vivo. a, GST–RHA3ACD 
possesses E3 ligase activity in vitro. An in vitro ubiquitination assay was 
performed with GST–RHA3ACD followed by deubiquitination reactions with 
GST–USP2-cc. N-ethylmaleimide (NEM) (10 mM), an inhibitor of 
deubiquitinases, and heat-inactivated (HI, 95 °C for 5 min) USP2-cc are 
controls. Samples were analysed by SDS–PAGE and silver staining. b, GST–
RHA3ACD possesses multi-monoubiquitination activity in vitro. A 
ubiquitination assay was done as in a but using the ubiquitin mutant with all 
lysine residues mutated to arginine (UBQ(K0)). Ubiquitinated proteins were 
detected by immunoblotting with anti-UBQ (left) or anti-RHA3A (right) 
antibodies. c, RHA3 expression in T-DNA insertion mutants. RHA3A expression 
in the T-DNA knockout line SALK_052714 and RHA3B expression in SALK_064303 
were analysed as in Extended Data Fig. 4b. Mean ± s.e.m. fold change (WT set as 
1.0); two-tailed Student’s t-test, n = 3. d, Screen for the optimal amiR-RHA3A and 
amiR-RHA3B. Protoplasts were transfected with RHA3A-HA or RHA3B-HA with 
control, amiR-RHA3A or amiR-RHA3B. RHA3A or RHA3B proteins were 
examined by immunoblotting with anti-HA antibody. e, RHA3A and RHA3B are 
required for BIK1 ubiquitination in vivo. A BIK1 ubiquitination assay was carried 
out by co-expressing control, artificial microRNA targeting RHA3A 
(amiR-RHA3A) or amiR-RHA3A together with microRNA targeting RHA3B 
(amiR-RHA3A amiR-RHA3B). f, RHA3A and RHA3B expression in amiR-RHA3A/B 
transgenic plants. qRT–PCR was carried out to detect RHA3A and RHA3B 
transcripts with ACTIN2 as a control. Mean ± s.e.m. fold change in gene 
expression from two independent transgenic lines (lines 1 and 2); one-way 
ANOVA, n = 5. g, RHA3A and RHA3B are required for BIK1 ubiquitination in 
transgenic plants. Protoplasts from amiR-RHA3A/B transgenic plants were 
transfected with BIK1–HA and FLAG–UBQ for ubiquitination assay. Bottom, 
quantification of BIK1 ubiquitination in amiR-RHA3A/B transgenic plants. 
Intensity of Ub-BIK1 or BIK1 bands was quantified with Image Lab (Bio-Rad). 
The amount of BIK1 ubiquitination is the relative intensity of the Ub-BIK1 band 
to the BIK1 band (no treatment in wild-type set as 1.0). Mean ± s.e.m.; different 
letters indicate significant difference with others (P < 0.05, one-way ANOVA, 
n = 3). h, Sequencing analysis of RHA3A and RHA3B genes in the CRISPR–Cas9 
rha3a/b mutant. PCR fragments corresponding to RHA3A and RHA3B in 
rha3a/b were amplified, sequenced, and aligned to wild-type coding 
sequences. The reverse complement of the PAM sequence is underlined in red, 
and red arrowheads indicate the theoretical Cas9 cleavage sites. The 
experiments were repeated three times with similar results.
Extended Data Fig. 6 | BIK1 in vitro ubiquitination sites identified by mass 
spectrometry. MS/MS spectra of peptides containing ubiquitinated lysine 
residues of BIK1. a, K31; b, K41; c, K95; d, K106; e, K170; f, K186; g, K286; h, K337; 
I, K366. MS spectra are outputs from the SEQUEST program. MS analysis was 
performed once.
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Extended Data Fig. 7 | BIK1 in vivo ubiquitination sites identified by mass 
spectrometry. a, Ubiquitinated BIK1–GFP in planta was immunoprecipitated 
for LC–MS/MS analysis. BIK1–GFP and FLAG–UBQ were co-expressed in 
wild-type protoplasts (about 4 × 106 cells) and then treated with 200 nM  
flg22 for 30 min. Ubiquitinated BIK1 was immunoprecipitated with 
GFP-trap-agarose, separated by SDS–PAGE, digested with trypsin and 
subjected to LC–MS/MS analysis. Portions of cell lysates were examined for 
BIK1–GFP expression (left), and immunoprecipitates were analysed by SDS–
PAGE following silver staining (middle; right for longer exposure of the same 
gel) and SDS–PAGE following CBB staining (right). The highlighted area was cut 
and analysed by MS. b, BIK1 is ubiquitinated in vivo. Ubiquitinated lysines 
containing a diglycine remnant identified by LC–MS/MS analysis are marked in 
red with amino acid positions. c–h, MS/MS spectra of peptides containing 
ubiquitinated lysines of BIK1 are shown. c, K31; d, K41; e, K95; f, K337; g, K358;  
h, K366. MS spectra are outputs from the SEQUEST program. MS analysis was 
performed once.
Extended Data Fig. 8 | BIK1 monoubiquitination is required for plant 
defence and flg22 signalling. a, BIK1(9KR) undergoes phosphorylation 
similar to BIK1 upon flg22 treatment. BIK1–HA or BIK1(9KR)–HA was expressed 
in wild-type protoplasts which were then treated with 100 nM flg22 for the 
indicated times. Band-shift of BIK1 was examined by immunoblotting with 
anti-HA antibody. b, BIK1(9KR) interacts with RHA3A in a co-IP assay. RHA3A–
HA was co-expressed with BIK1–FLAG or BIK1(9KR)–FLAG in protoplasts that 
were then treated with 100 nM flg22 for 15 min. Co-IP assay was carried out with 
anti-FLAG agarose and immunoprecipitated proteins were immunoblotted 
with anti-HA or anti-FLAG antibody (top two panels). Bottom two panels show 
BIK1–FLAG or BIK1(9KR)–FLAG and RHA3A–HA proteins. c, Transgenic plants 
with BIK19KR overexpression in wild-type background show similar MAPK 
activation to wild-type plants. Eleven-day-old seedlings of wild-type or 
35S::BIK19KR-HA/ WT transgenic plants (lines 55 and 56) were treated with 
200 nM flg22 for 15 min. MAPK activation was analysed with anti-pERK 
antibody (top), and protein loading is shown by CBB staining for RBC (bottom). 
d, Transgenic plants with BIK19KR overexpression in wild-type background show 
similar flg22-induced ROS production to wild-type plants. Leaf discs from the 
indicated genotypes were treated with 100 nM flg22, and ROS production was 
measured as relative luminescence units by a luminometer over 50 min. Mean 
total photon count ± s.e.m. overlaid with dot plot (one-way ANOVA, n = 16).  
e, Growth phenotype of pBIK1::BIK1-HA/bik1 and pBIK1::BIK19KR-HA/bik1 
transgenic plants. Five-week-old soil-grown plants are shown. Scale bar, 1 cm.  
f, Expression of BIK1–HA or BIK1(9KR)–HA in transgenic plants. Top, total 
proteins from leaves of four-week-old transgenic plants were subjected to 
anti-HA immunoblotting. Bottom, CBB staining for RBC. g, RHA3A and RHA3B 
are involved in resistance to Pst DC3000 hrcC− infection. Plants were 
spray-inoculated with Pst DC3000 hrcC− and bacterial growth was measured at 
4 dpi. Mean ± s.e.m. overlaid with dot plots (one-way ANOVA, n = 6). h, RHA3A 
and RHA3B are involved in resistance to Botrytis. Four-week-old plant leaves 
were deposited with 10 μl B. cinerea BO5 at a concentration of 2.5 × 105 spores 
per ml. Disease symptoms were recorded, and the lesion diameter was 
measured at 2 dpi. Mean ± s.e.m. overlaid with dot plots (one-way ANOVA, 
n = 34). i, ROS production is reduced in rha3a/b plants. Leaf discs from 
wild-type or rha3a/b plants were treated with 100 nM flg22 and ROS 
production measured over 50 min. Mean ± s.e.m. total photon count overlaid 
with dot plots (two-tailed Student’s t-test, n = 36 for wild-type and n = 32 for 
rha3a/b). j, RHA3A and RHA3B are involved in resistance to Pst DC3000. Plants 
were spray-inoculated with Pst DC3000 and bacterial growth was measured at 
3 dpi. Mean ± s.e.m. overlaid with dot plots (two-tailed Student’s t-test, n = 9). 
Experiments were repeated three times with similar results.
Article
Extended Data Fig. 9 | The BIK1(9KR) mutation impairs flg22-induced 
endocytosis of BIK1. a, b, BIK1(9KR)–GFP puncta colocalize less than BIK1–
GFP with FM4-64 upon treatment with flg22. a, Five-day-old 35S::BIK1-GFP or 
35S::BIK19KR-GFP seedlings were pretreated with FM4-64 (2 μM) for 15 min and 
elicited with 100 nM flg22 for the indicated times; fluorescence was detected in 
epidermis using confocal microscopy. White arrows, colocalized endosomes. 
Scale bars, 20 μm. b, Percentage of endosomes positive for BIK1–GFP or 
BIK1(9KR)–GFP and FM4-64 over time per 100% of image area. Mean ± s.e.m. 
overlaid with dot plots (two-tailed Student’s t-test, n = 21 images for BIK1–GFP 
and n = 16, 15 images for 10, 15 min, respectively, for BIK1(9KR)–GFP).  
c, Flg22-induced endocytosis of BIK1, BIK1(9KR) and FLS2 in N. benthamiana. 
BIK1–TagRFP (BIK1–RFP) or BIK1(9KR)–TagRFP (BIK1(9KR)–RFP) was 
co-expressed with FLS2–YFP in N. benthamiana, infiltrated with 100 μM flg22 
and imaged at the indicated time points by confocal microscopy. Images at  
30–40, 40–50 and 50–60 min after flg22 treatment from Fig. 4e are shown 
here. Scale bars, 20 μm. For BIK1–RFP/FLS2–YFP, n = 14, 11, 7, 10, 10, 6, 7 images 
for 0, 10–20, 20–30, 30–40, 40–50, 50–60, 100–120 min; for BIK1(9KR)–RFP/
FLS2–YFP, n = 19, 11, 11, 9, 16, 12, 7 images for 0, 10–20, 20–30, 30–40, 40–50,  
50–60, 100–120 min, respectively. d, Percentage of BIK1–RFP puncta that 
colocalized with FLS2–YFP after treatment with flg22 for the indicated times in 
c and Fig. 4e. Mean ± s.e.m. overlaid with dot plots (n = 14, 11, 7, 10, 10, 6, 7 images 
for 0, 10–20, 20–30, 30–40, 40–50, 50–60, 100–120 min, respectively).  
e, f, BIK1(9KR)–RFP shows reduced colocalization with ARA6–YFP.  
e, BIK1–RFP or BIK1(9KR)–RFP was transiently expressed with ARA6–YFP in  
N. benthamiana, and the images were taken 48–72 h after infiltration. Scale 
bars, 10 μm. f, Percentage of BIK1–RFP puncta that colocalized with ARA6–YFP. 
Mean ± s.e.m. overlaid with dot plots (two-tailed Student’s t-test, n = 9 images 
for BIK1–RFP; n = 10 images for BIK1(9KR)–RFP). Experiments were repeated 
three times with similar results.
Extended Data Fig. 10 | Monoubiquitination mediates release of BIK1 from 
the plasma membrane upon ligand detection. a, PYR-41 impairs 
flg22-induced dissociation of BIK1 from FLS2. FLS2–HA was co-expressed with 
BIK1–FLAG or control in protoplasts. After pretreatment with 50 μM PYR-41 for 
30 min, protoplasts were stimulated with 100 nM flg22 for 15 min. Co-IP and 
immunoblotting were performed as in Fig. 4g. b, A working model of 
RHA3A/B-mediated BIK1 monoubiquitination in plant immunity. Under 
non-activated, steady-state conditions (0 min), BIK1 remains 
hypo-phosphorylated and associates with FLS2 and BAK1. Upon flg22 
detection, FLS2 dimerizes with BAK1, which stimulates BIK1 phosphorylation 
(<1 min). Phosphorylated BIK1 is monoubiquitinated by the E3 ligases RHA3A 
and RHA3B, leading to dissociation of BIK1 from the FLS2–BAK1 complex, 
accompanied by endocytosis (10–20 min). Ligand-induced 
monoubiquitination of BIK1 contributes to the activation of ROS and other 
defence responses. FLS2 is polyubiquitinated and endocytosed 40 min after 
detection of flg22 to attenuate signalling. c, BIK1(9KR) shows comparable 
protein expression to BIK1 in transgenic plants. 35S::BIK1-HA or 35S::BIK19KR-HA 
transgenic plants in wild-type background were used for immunoblotting to 
detect BIK1 proteins with anti-HA antibody. Control, empty vector. d, Stability 
of BIK1 and BIK1(9KR) proteins after treatment with cycloheximide (CHX). 
BIK1–HA or BIK1(9KR)–HA was expressed in wild-type protoplasts for 12 h 
followed by treatment with 500 μg/ml CHX for the indicated time. BIK1 or 
BIK1(9KR) proteins were analysed by immunoblotting with anti-HA antibody. 
Asterisk indicates that CHX was added immediately after transfection, thus 
blocking protein synthesis. Experiments were repeated three times with 
similar results.
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The statistical test(s) used AND whether they are one- or two-sided 
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Software and code
Policy information about availability of computer code
Data collection Image J (version 1.51), Image Lab (Bio-Rad, version 4.1), LAS-X (Leica, version 3.5.6.21594) were used in data collection.
Data analysis Images from Immuno Blotting were quantified with Image LabTM (Bio-Rad, version 4.1). Confocal images were analyzed with LAS-X 
(Leica, version 3.5.6.21594), ZEN (Zeiss). Statistical analysis was performed with Microsoft Excel 2016. The MS/MS spectra were analyzed 
with SEQUEST (version 28). Crystal structure was analyzed with PyMOL (version 2.1). 
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- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
The data supporting the findings of this study are available within the paper and its Supplementary Information files. Source Data (gels and graphs) for Figs. 1–4 and 
Extended Data Figs. 1–10 are provided with the paper.
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Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size No statistical methods were used to predetermine sample sizes. Sample sizes were determined based on previous publications on similar 
experiments. The sample sizes were sufficient as the differences between experimental groups were reproducible.
Data exclusions No data were excluded from analyses in the experiments.
Replication All attempts to replicate the experiments were successful. Number of repeats was given in the figure legends. 
Randomization Plant materials used in the study were collected randomly.
Blinding Investigators were not blinded to plant genotypes during experiments. The research materials are plants so the blinding design is not 
applicable to this system. Experiment results are not subjective.
Behavioural & social sciences study design
All studies must disclose on these points even when the disclosure is negative.
Study description Briefly describe the study type including whether data are quantitative, qualitative, or mixed-methods (e.g. qualitative cross-sectional, 
quantitative experimental, mixed-methods case study). 
Research sample State the research sample (e.g. Harvard university undergraduates, villagers in rural India) and provide relevant demographic information 
(e.g. age, sex) and indicate whether the sample is representative. Provide a rationale for the study sample chosen. For studies involving 
existing datasets, please describe the dataset and source.
Sampling strategy Describe the sampling procedure (e.g. random, snowball, stratified, convenience). Describe the statistical methods that were used to 
predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale 
for why these sample sizes are sufficient. For qualitative data, please indicate whether data saturation was considered, and what criteria 
were used to decide that no further sampling was needed.
Data collection Provide details about the data collection procedure, including the instruments or devices used to record the data (e.g. pen and paper, 
computer, eye tracker, video or audio equipment) whether anyone was present besides the participant(s) and the researcher, and whether 
the researcher was blind to experimental condition and/or the study hypothesis during data collection.
Timing Indicate the start and stop dates of data collection. If there is a gap between collection periods, state the dates for each sample cohort.
Data exclusions If no data were excluded from the analyses, state so OR if data were excluded, provide the exact number of exclusions and the rationale 
behind them, indicating whether exclusion criteria were pre-established.
Non-participation State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no 
participants dropped out/declined participation.
Randomization If participants were not allocated into experimental groups, state so OR describe how participants were allocated to groups, and if 
allocation was not random, describe how covariates were controlled.
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Ecological, evolutionary & environmental sciences study design
All studies must disclose on these points even when the disclosure is negative.
Study description Briefly describe the study. For quantitative data include treatment factors and interactions, design structure (e.g. factorial, nested, 
hierarchical), nature and number of experimental units and replicates.
Research sample Describe the research sample (e.g. a group of tagged Passer domesticus, all Stenocereus thurberi within Organ Pipe Cactus National 
Monument), and provide a rationale for the sample choice. When relevant, describe the organism taxa, source, sex, age range and 
any manipulations. State what population the sample is meant to represent when applicable. For studies involving existing datasets, 
describe the data and its source.
Sampling strategy Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size 
calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.
Data collection Describe the data collection procedure, including who recorded the data and how.
Timing and spatial scale Indicate the start and stop dates of data collection, noting the frequency and periodicity of sampling and providing a rationale for 
these choices. If there is a gap between collection periods, state the dates for each sample cohort. Specify the spatial scale from which 
the data are taken
Data exclusions If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, 
indicating whether exclusion criteria were pre-established.
Reproducibility Describe the measures taken to verify the reproducibility of experimental findings. For each experiment, note whether any attempts to 
repeat the experiment failed OR state that all attempts to repeat the experiment were successful.
Randomization Describe how samples/organisms/participants were allocated into groups. If allocation was not random, describe how covariates were 
controlled. If this is not relevant to your study, explain why.
Blinding Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why 
blinding was not relevant to your study.
Did the study involve field work? Yes No
Field work, collection and transport
Field conditions Describe the study conditions for field work, providing relevant parameters (e.g. temperature, rainfall).
Location State the location of the sampling or experiment, providing relevant parameters (e.g. latitude and longitude, elevation, water 
depth).
Access and import/export Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and 
in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing 
authority, the date of issue, and any identifying information).
Disturbance Describe any disturbance caused by the study and how it was minimized.
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Human research participants
Methods
n/a Involved in the study
ChIP-seq
Flow cytometry
MRI-based neuroimaging
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Unique biological materials
Policy information about availability of materials
Obtaining unique materials Describe any restrictions on the availability of unique materials OR confirm that all unique materials used are readily available 
from the authors or from standard commercial sources (and specify these sources).
Antibodies
Antibodies used Anti-HA-Peroxidase, Roche, Cat # 12013819001, clone 3F10. Dilution 1: 2,000. 
Anti-FLAG-Peroxidase, Sigma-Aldrich, Cat # A8592, clone M2. Dilution 1: 2,000. 
Anti-GST, Santa Cruz, Cat # SC-53909, clone 1E5. Dilution 1: 2,000. 
Anti-ubiquitin (P4D1), Santa Cruz, Cat # SC-8017, clone P4D1. Dilution 1:500. 
Anti-GFP, Roche, Cat # 11814460001, mix of clone 7.1 and 13.1. Dilution 1: 2,000. 
Anti-Phospho-p44/42 MAPK, Cell Signaling, Cat # 9101. Polyclone. Dilution 1: 2,000.  
Anti-Rabbit IgG, HRP-linked antibody, Cell Signaling, Cat # 7074. Polyclone. Dilution 1: 10,000. 
Anti-Mouse IgG, HRP-linked antibody, Cell Signaling, Cat # 7076. Polyclone. Dilution 1: 10,000. 
Anti-FLAG M2 Affinity gel, Sigma-Aldrich, Cat # 2220, clone M2.  
Anti-MBP, Biolegend, Cat # 906901, clone YM-2. Dilution 1: 1,000.  
Anti-RHA3A, GenScript, generated with peptide AGGDSPSPNKGLKKC. Polyclone. Dilution 1:1,000. 
 
Validation Validation statements, relevant citations of commercial primary antibodies are available from manufacturers: 
Anti-HA-Peroxidase, Roche, Cat # 12013819001, clone 3F10. https://www.sigmaaldrich.com/catalog/product/
roche/12013819001?lang=en&region=US 
Anti-FLAG-Peroxidase, Sigma-Aldrich, Cat # A8592, clone M2. https://www.sigmaaldrich.com/catalog/product/sigma/a8592?
lang=en&region=US 
Anti-GST, Santa Cruz, Cat # SC-53909, clone 1E5. https://www.scbt.com/p/gst-antibody-1e5 
Anti-ubiquitin (P4D1), Santa Cruz, Cat # SC-8017, clone P4D1. https://www.scbt.com/p/ub-antibody-p4d1 
Anti-GFP, Roche, Cat # 11814460001, mix of clone 7.1 and 13.1. https://www.sigmaaldrich.com/catalog/product/
roche/11814460001?lang=en&region=US 
Anti-Phospho-p44/42 MAPK, Cell Signaling, Cat # 9101. https://www.cellsignal.com/products/primary-antibodies/phospho-
p44-42-mapk-erk1-2-thr202-tyr204-antibody/9101 
Anti-Rabbit IgG, HRP-linked antibody, Cell Signaling, Cat # 7074. https://www.cellsignal.com/products/secondary-antibodies/
anti-rabbit-igg-hrp-linked-antibody/7074 
Anti-Mouse IgG, HRP-linked antibody, Cell Signaling, Cat # 7076. https://www.cellsignal.com/products/secondary-antibodies/
anti-mouse-igg-hrp-linked-antibody/7076 
Anti-FLAG M2 Affinity gel, Sigma-Aldrich, Cat # 2220, clone M2. https://www.sigmaaldrich.com/catalog/product/sigma/a2220?
lang=en&region=US 
Anti-MBP, Biolegend, Cat # 906901, clone YM-2. https://www.biolegend.com/en-gb/products/purified-anti-maltose-binding-
protein-mbp-antibody-11081 
Anti-RHA3A, GenScript, generated with peptide AGGDSPSPNKGLKKC from Rabbit. Figure 2d bottom panel supports the anti-
RHA3A antibody do not have cross reactivity with other protein including E1, E2, BIK1 or Ubiquitin. 
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s) State the source of each cell line used.
Authentication Describe the authentication procedures for each cell line used OR declare that none of the cell lines used were authenticated.
Mycoplasma contamination Confirm that all cell lines tested negative for mycoplasma contamination OR describe the results of the testing for 
mycoplasma contamination OR declare that the cell lines were not tested for mycoplasma contamination.
Commonly misidentified lines
(See ICLAC register)
No commonly misidentified cell lines were used.
Palaeontology
Specimen provenance Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the 
issuing authority, the date of issue, and any identifying information).
Specimen deposition Indicate where the specimens have been deposited to permit free access by other researchers.
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Dating methods If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), 
where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new 
dates are provided.
Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals For laboratory animals, report species, strain, sex and age OR state that the study did not involve laboratory animals.
Wild animals Provide details on animals observed in or captured in the field; report species, sex and age where possible. Describe how animals 
were caught and transported and what happened to captive animals after the study (if killed, explain why and describe method; if 
released, say where and when) OR state that the study did not involve wild animals.
Field-collected samples For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, 
photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.
Human research participants
Policy information about studies involving human research participants
Population characteristics Describe the covariate-relevant population characteristics of the human research participants (e.g. age, gender, genotypic 
information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design 
questions and have nothing to add here, write "See above."
Recruitment Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how 
these are likely to impact results.
ChIP-seq
Data deposition
Confirm that both raw and final processed data have been deposited in a public database such as GEO.
Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.
Data access links 
May remain private before publication.
For "Initial submission" or "Revised version" documents, provide reviewer access links.  For your "Final submission" document, 
provide a link to the deposited data.
Files in database submission Provide a list of all files available in the database submission.
Genome browser session 
(e.g. UCSC)
Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to 
enable peer review.  Write "no longer applicable" for "Final submission" documents.
Methodology
Replicates Describe the experimental replicates, specifying number, type and replicate agreement.
Sequencing depth Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of 
reads and whether they were paired- or single-end.
Antibodies Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone 
name, and lot number.
Peak calling parameters Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and 
index files used.
Data quality Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold 
enrichment.
Software Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a 
community repository, provide accession details.
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Flow Cytometry
Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation Describe the sample preparation, detailing the biological source of the cells and any tissue processing steps used.
Instrument Identify the instrument used for data collection, specifying make and model number.
Software Describe the software used to collect and analyze the flow cytometry data. For custom code that has been deposited into a 
community repository, provide accession details.
Cell population abundance Describe the abundance of the relevant cell populations within post-sort fractions, providing details on the purity of the samples 
and how it was determined.
Gating strategy Describe the gating strategy used for all relevant experiments, specifying the preliminary FSC/SSC gates of the starting cell 
population, indicating where boundaries between "positive" and "negative" staining cell populations are defined.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
Magnetic resonance imaging
Experimental design
Design type Indicate task or resting state; event-related or block design.
Design specifications Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial 
or block (if trials are blocked) and interval between trials.
Behavioral performance measures State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used 
to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across 
subjects).
Acquisition
Imaging type(s) Specify: functional, structural, diffusion, perfusion.
Field strength Specify in Tesla
Sequence & imaging parameters Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, 
slice thickness, orientation and TE/TR/flip angle.
Area of acquisition State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.
Diffusion MRI Used Not used
Preprocessing
Preprocessing software Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, 
segmentation, smoothing kernel size, etc.).
Normalization If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types 
used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.
Normalization template Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g. 
original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.
Noise and artifact removal Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and 
physiological signals (heart rate, respiration).
Volume censoring Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.
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Statistical modeling & inference
Model type and settings Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first 
and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).
Effect(s) tested Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether 
ANOVA or factorial designs were used.
Specify type of analysis: Whole brain ROI-based Both
Statistic type for inference
(See Eklund et al. 2016)
Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.
Correction Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte 
Carlo).
Models & analysis
n/a Involved in the study
Functional and/or effective connectivity
Graph analysis
Multivariate modeling or predictive analysis
Functional and/or effective connectivity Report the measures of dependence used and the model details (e.g. Pearson correlation, partial 
correlation, mutual information).
Graph analysis Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, 
subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, 
etc.).
Multivariate modeling and predictive analysis Specify independent variables, features extraction and dimension reduction, model, training and evaluation 
metrics.
